Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Open-Label Trial Evaluating The Safety, Tolerability And Pharmacokinetics Of VB-1953 For The Treatment Of Patients With Moderate To Severe Facial Acne Vulgaris When Administered As A Topical Gel

Next Previous
Trial Profile

A Phase I Open-Label Trial Evaluating The Safety, Tolerability And Pharmacokinetics Of VB-1953 For The Treatment Of Patients With Moderate To Severe Facial Acne Vulgaris When Administered As A Topical Gel

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VB 1953 (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

  • 11 Jan 2020 Results assessing clinical pharmacokinetics, safety and exploratory efficacy study of a Topical Bactericidal VB-1953 published in the Clinical Drug Investigation
  • 07 Feb 2017 Primary endpoint (Pharmacokinetics (plasma concentration less than 1 ng/ml)) has been met, according to top-line results published in a Vyome Biosciences Media Release.
  • 07 Feb 2017 Top-Line results (n=12) published in a Vyome Biosciences Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top